AbbVie to CoDevelop Teneobios Lead Candidate for Multiple Myeloma Gains Acquisition Option

AbbVie to Co-Develop Teneobio’s Lead Candidate for Multiple Myeloma, Gains Acquisition Option

AbbVie will partner with Teneobio to develop and commercialize its lead program, the preclinical cancer immunotherapy candidate TNB-383B for multiple myeloma, through a collaboration that gives AbbVie the option to buy the startup. TNB-383B is a bispecific antibody designed to simultaneously target B-cell maturation antigen (BCMA) and cluster of differentiation 3 (CD3). TNB-383B is among […]

More From BioPortfolio on "AbbVie to Co-Develop Teneobio’s Lead Candidate for Multiple Myeloma, Gains Acquisition Option"